Broadening the Therapeutic Armamentarium Against Plaque Psoriasis
Podcast 2
Post-Test/Evaluation
Questions marked with a
*
are required
19%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
A 20-year-old man presents to dermatology with severe psoriasis (13% body surface area) on his
face, chest, back, arms, and legs. He has tried topical OTC agents and hydrocortisone cream.
When discussing systemic treatment for this patient, he voices that he doesn’t want treatment
requiring injections. Which of the following agents – recently approved based on positive PASI 75
and PASI 90 data versus apremilast – might make the most sense for him?
Deucravacitinib
Upadacitinib
Bimekizumab
Tofacitinib
When talking to patients about treatment, it is critical to understand individual patient goals.
Data show that which of the following is the most critical patient-reported treatment goal?
Increasing mobility
Reducing skin symptoms (itching, pain, appearance, etc)
Reducing joint symptoms
Reducing fatigue
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close